Fulcrum Therapeutics (NASDAQ:FULC), trading on NASDAQ under the symbol FULC, is a clinical-stage biopharmaceutical company dedicated to discovering and developing precision therapies that address dysregulated gene expression. The company’s scientific focus centers on epigenetic regulation and transcription control, leveraging small molecules to modulate key regulatory proteins. By targeting genetic switches at the molecular level, Fulcrum aims to transform treatments for rare diseases and genetically defined conditions where existing therapeutic options are limited or non-existent.
The company’s lead product candidate, losmapimod, is an oral inhibitor of p38 MAP kinase being evaluated for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a rare muscle disorder characterized by progressive skeletal muscle weakness. Losmapimod has advanced through clinical trials, demonstrating target engagement and potential benefit in muscle function and disease biomarkers. Beyond FSHD, Fulcrum’s pipeline includes preclinical programs in other genetically driven diseases, with research efforts spanning neuromuscular, ophthalmic, and inflammatory conditions that share underlying epigenetic dysregulation.
Founded in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum has assembled a team of experts in molecular biology, medicinal chemistry, and clinical development. The company’s research operations extend to partnerships and collaborations in both North America and Europe, ensuring access to diverse patient populations and specialized clinical trial sites. Fulcrum’s infrastructure supports a modular approach to drug discovery, combining in-house capabilities with strategic alliances in academia and industry to accelerate the translation of novel science into therapeutic candidates.
Under the leadership of President and Chief Executive Officer Roger Tung, Fulcrum has grown from a small startup into a publicly traded enterprise with a robust pipeline. The senior management team brings extensive experience from leading biopharmaceutical firms, spanning drug discovery, regulatory affairs, and commercial strategy. Fulcrum’s board of directors includes seasoned industry veterans who guide corporate governance and strategic decision-making as the company advances its mission to develop first-in-class treatments for patients with high unmet medical needs.
